A similar scenario was reported by Atefi et al. that identified the activation of Akt/mTOR signaling as a prominent mechanism of cross-resistance to BRAF and MEK inhibitors that can be reversed in vitro by the concomitant pharmacological inhibition of Akt or mTOR in both patient-derived and established melanoma cell lines [293]. The gene discussed is MTOR; the disease is melanoma.